<?xml version='1.0' encoding='utf-8'?>
<document id="25280537"><sentence text="Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C &gt; T variants: a case report."><entity charOffset="0-8" id="DDI-PubMed.25280537.s1.e0" text="Creatine" /><entity charOffset="53-64" id="DDI-PubMed.25280537.s1.e1" text="fluvastatin" /><entity charOffset="69-80" id="DDI-PubMed.25280537.s1.e2" text="telmisartan" /><entity charOffset="115-123" id="DDI-PubMed.25280537.s1.e3" text="CYP2C9*3" /><pair ddi="false" e1="DDI-PubMed.25280537.s1.e0" e2="DDI-PubMed.25280537.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25280537.s1.e0" e2="DDI-PubMed.25280537.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25280537.s1.e0" e2="DDI-PubMed.25280537.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25280537.s1.e0" e2="DDI-PubMed.25280537.s1.e3" /><pair ddi="false" e1="DDI-PubMed.25280537.s1.e1" e2="DDI-PubMed.25280537.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25280537.s1.e1" e2="DDI-PubMed.25280537.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25280537.s1.e1" e2="DDI-PubMed.25280537.s1.e3" /><pair ddi="false" e1="DDI-PubMed.25280537.s1.e2" e2="DDI-PubMed.25280537.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25280537.s1.e2" e2="DDI-PubMed.25280537.s1.e3" /></sentence><sentence text="Genetic factors as predictor of the individual outcome of drug therapy is one aim of personalized medicine approaches" /><sentence text="" /><sentence text="We report a drug metabolism based analysis of genetic polymorphisms in a Caucasian patient receiving fluvastatin and telmisartan experiencing myotoxicity (myalgia and moderate creatine kinase elevation)"><entity charOffset="101-112" id="DDI-PubMed.25280537.s4.e0" text="fluvastatin" /><entity charOffset="117-128" id="DDI-PubMed.25280537.s4.e1" text="telmisartan" /><pair ddi="false" e1="DDI-PubMed.25280537.s4.e0" e2="DDI-PubMed.25280537.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25280537.s4.e0" e2="DDI-PubMed.25280537.s4.e1" /></sentence><sentence text="" /><sentence text="The obtained findings suggest that heterocygocity of cytochrome P450 CYP2C9*3 variant in combination with multidrug resistance-associated protein MRP2-24C &gt; T functions as risk factor predisposing to experience drug-drug interaction combing those drugs" /><sentence text="" /></document>